

Special Issue

The Immunology of Hepatocellular Carcinoma: Towards the Future of Immunotherapy

Message from the Guest Editors

Critical information and assessment are needed to advance the research into better and more effective immunotherapeutic strategies in HCC. Hence, this Special Issue “The immunology of Hepatocellular Carcinoma: towards the future of immunotherapy” will focus on deeper understanding of the basis of immune circuits in HCC with the special focus on its immune landscapes and on the solid rationale in designing combination immunotherapy strategies with enhanced efficacy as well as tolerable and manageable irAEs.

Keywords:

- Immune microenvironment
- tumour immunology
- hepatocellular carcinoma
- immunotherapy
- chronic hepatitis infection
- cancer vaccines
- chronic liver inflammation
- non-alcoholic fatty liver disease

Guest Editors

Dr. Valerie Chew

Duke-NUS Medical School Singapore, Singapore City, Singapore

Dr. Diamantis I. Tsilimigras

Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, 395 W. 12th Ave., Columbus, OH 43210, USA

Deadline for manuscript submissions

closed (1 March 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/41570

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).